Predict your next investment

Khondrion company logo
HEALTHCARE | Pharmaceuticals / Drugs
khondrion.com

See what CB Insights has to offer

Stage

Grant | Alive

About Khondrion

Khondrion is a clinical-stage pharmaceutical company focusing on developing small-molecule therapeutics for mitochondrial diseases.

Khondrion Headquarter Location

Philips van Leydenlaan 15

Nijmegen, 6525,

Netherlands

+31 243610639

Latest Khondrion News

Khondrion announces publication in PLOS ONE of new research showing normalisation of prostate cancer stem cell mPGES-1 overexpression and inhibition of cancer spheroid growth by sonlicromanol’s active metabolite

Jul 16, 2021

Khondrion announces publication in PLOS ONE of new research showing normalisation of prostate cancer stem cell mPGES-1 overexpression and inhibition of cancer spheroid growth by sonlicromanol’s active metabolite 16 juli 2021 Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the publication of new research in PLOS ONE examining the in vivo active metabolite of sonlicromanol, as a selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1)-mediated PGE2 synthesis in prostate cancer stem cells and its potential as a novel treatment approach for prostate cancer and other cancers with high mPGES-1 expression. Sonlicromanol (KH176) is Khondrion’s wholly-owned investigational lead asset, currently in phase IIb development as a potentially disease-modifying treatment for mitochondrial disease. The Company has previously demonstrated the ability of sonlicromanol’s active metabolite to selectively inhibit mPGES-1, a key enzyme involved in the production of prostaglandin E2. This prostaglandin, known to induce and propagate the inflammation response, was found in significantly increased levels in cells derived from mitochondrial disease patients. Importantly, the aggressiveness of cancers, like prostate cancer, has also been found in independent studies to be associated with elevated expression of mPGES-1. The new research, authored by Khondrion, details the effects of selective mPGES-1 targeting by sonlicromanol’s active metabolite, and examines its potential to decrease the aggressiveness of prostate cancer by inhibiting mPGES-1 expression. The research team found that inhibition of mPGES-1 by sonlicromanol’s metabolite was able to considerably reduce spheroid growth in the human prostate cancer cell line DU145, potentially offering a novel approach in treating prostate cancer and other malignancies with high expression of mPGES-1. Sonlicromanol’s active metabolite was found to reduce the constitutively high mPGES-1 levels. The growth of spheroids in a physiological relevant 3D environment for tumour cells was reduced and the prostate cancer stem cell population was selectively decreased. These findings are of particular interest as they further strengthen earlier research indicating the potential of sonlicromanol [human plasma exposure at steady-state: active metabolite = ½ KH176] as a treatment for patients with high mPGES-1 expression and signal its potential as an anti-tumour drug, based on its ability to decrease the size of cancer stem cell-formed spheroids. Dr. Herma Renkema, Chief Early Development Officer at Khondrion and co-author of the paper, said: “These are significant findings that build on our earlier research into the anti-inflammatory effect of sonlicromanol and its potential as a disease-modifying drug for patients with mitochondrial disease. That research led us to explore the potential of this compound beyond mitochondrial disease, given what we know about its mode of action. Inhibition of mPGES-1 expression is an approach currently being investigated to identify new therapeutic avenues for prostate cancer, which is the most frequently diagnosed cancer in the Western world and the leading cause of cancer-related death in men over 65 years of age. Our research provides compelling evidence to support further studies investigating the potential of sonlicromanol as an anti-tumour drug in prostate and other human cancers.” A link to the study – Jiang, X., Renkema, H., Smeitink, J., Beyrath J. Sonlicromanol’s active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth. PLoS ONE 16(7): e0254315 (2021) – can be found here: https://doi.org/10.1371/journal.pone.0254315

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Khondrion Patents

Khondrion has filed 5 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Chronic fatigue syndrome
  • Neurological disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/7/2016

10/27/2020

Rare diseases, Human proteins, Cellular respiration, Proteins, Autosomal recessive disorders

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/7/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/27/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Rare diseases, Human proteins, Cellular respiration, Proteins, Autosomal recessive disorders

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Khondrion Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Khondrion Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.